FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:416-418 July 27, 2006 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Julius, S. PubMed Citation

To the Editor: The study by Julius et al. of the efficacy of candesartan for prehypertension (April 20 issue)¹ demonstrates what seemed obvious: if patients with prehypertension receive hypotensive drugs, arterial hypertension will develop in fewer of them because they are already being treated. This prediction was borne out in the study, but as compared with placebo, candesartan did not reduce cardiovascular events during the study period.

The question is, does the administration of a hypotensive drug at a fixed dose reduce the cardiovascular morbidity and mortality in patients with prehypertension, as compared with the use of nonpharmacologic treatment and . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.